

# Ken Ogasawara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4437798/publications.pdf>

Version: 2024-02-01

51  
papers

3,119  
citations

257101

24  
h-index

182168

51  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet, The</i> , 2020, 396, 839-852.	6.3	1,224
2	Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 2294-2308.	6.3	273
3	Genetic Polymorphism of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) as a Risk Factor for Coronary Artery Disease. <i>Circulation</i> , 1997, 95, 2032-2036.	1.6	227
4	Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. <i>Journal of Human Genetics</i> , 2009, 54, 40-46.	1.1	79
5	Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. <i>Molecular Pharmaceutics</i> , 2018, 15, 2621-2632.	2.3	76
6	Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F165-F170.	1.3	74
7	Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1143-1152.	1.1	73
8	Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study. <i>Blood</i> , 2021, 138, 91-91.	0.6	70
9	Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2013, 52, 751-762.	1.6	68
10	Hepatitis C Virus-related Cirrhosis is a Major Determinant of the Expression Levels of Hepatic Drug Transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 190-199.	1.1	66
11	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	0.6	66
12	Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2022, 23, 1066-1077.	5.1	62
13	Hepatocyte nuclear factor-4 $\beta$ regulates the human organic anion transporter 1 gene in the kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F1819-F1826.	1.3	53
14	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 281-288.	1.1	51
15	Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. <i>Journal of Human Genetics</i> , 2008, 53, 607-614.	1.1	42
16	Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2020, 136, 39-40.	0.6	40
17	Critical roles of Sp1 in gene expression of human and rat H <sup>+</sup> /organic cation antiporter MATE1. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1564-F1570.	1.3	38
18	Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1169-1177.	1.1	37

#	ARTICLE	IF	CITATIONS
19	Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. <i>Xenobiotica</i> , 2013, 43, 229-235.	0.5	36
20	Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis. <i>Pharmaceutical Research</i> , 2005, 22, 2016-2022.	1.7	35
21	Human Organic Anion Transporter 3 Gene Is Regulated Constitutively and Inducibly via a cAMP-Response Element. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 317-322.	1.3	35
22	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F247-F252.	1.3	34
23	Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS. <i>Journal of Proteome Research</i> , 2017, 16, 4134-4143.	1.8	34
24	Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). <i>Blood</i> , 2021, 138, 2840-2840.	0.6	34
25	Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1621-1633.	1.6	25
26	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 2207-2218.	2.5	24
27	Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 891-898.	1.1	21
28	Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 217-227.	1.6	21
29	Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 647-656.	0.7	20
30	Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. <i>Xenobiotica</i> , 2013, 43, 641-649.	0.5	19
31	Characterization of the Basal Promoter Element of Human Organic Cation Transporter 2 Gene. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 684-689.	1.3	17
32	Exposureâ€” and Doseâ€”response Analyses in Dose Selection and Labeling of FDA-approved Biologics. <i>Clinical Therapeutics</i> , 2018, 40, 95-102.e2.	1.1	14
33	<i>In Vivo</i> Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 81-89.	2.3	14
34	Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 899-906.	1.1	13
35	Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT. <i>Blood</i> , 2019, 134, 2868-2868.	0.6	13
36	Pharmacokinetics of Total and Unbound Prednisone and Prednisolone in Stable Kidney Transplant Recipients With Diabetes Mellitus. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 448-455.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 941-952.	1.1	10
38	Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 307-314.	1.1	9
39	Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 87-95.	1.1	9
40	Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>Cancer Medicine</i> , 2022, 11, 4889-4899.	1.3	8
41	A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 995-1001.	1.1	6
42	Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1620-1631.	1.0	5
43	Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 752-758.	0.8	5
44	Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 369-377.	1.1	5
45	Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1109-1117.	1.1	5
46	Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 1762-1762.	0.6	5
47	Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 366-375.	0.8	4
48	Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S25-S26.	2.0	3
49	Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S207-S208.	0.6	3
50	Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 914-921.	0.8	3
51	Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide. <i>Pediatric Research</i> , 2021, 90, 832-839.	1.1	1